Pituitary Dopaminergic System in Patients with Myotonie Dystrophy. Tohoku J. exp. Med., 1988, 156 (3), 291-298 -We studied the function of hypothalamo-pituitary dopaminergic system in 15 myotonic dystrophy (MyD) patients whose growth hormone (GH) responses to insulin or arginine had been normal. We obtained the following findings : (1) basal levels of plasma GH and prolactin (PRL) were normal, although the latter levels were slightly lower than controls, (2) both GH and PRL responses to L-dopa or bromocriptine were significantly blunted compared with controls, (3) PRL response to sulpiride was also significantly low compared with controls. These results indicate that hypoth alamic dopaminergic neuron and its postsynaptic dopamine receptors relating to GH secretion might be impaired. It was also suggested that the dopamine rece ptors of pituitary PRL cells might be impaired and the PRL reserve of pituitary cells might be decreased in some case. myotonic dystrophy ; hypo thalamo-pituitary dopaminergic system ; growth hormone ; prolactin
It is well-known that patients with myotonic muscular dystrophy (MyD) show complications of endocrine disorders (Roses et al. 1979) , including the hypothalamo-pituitary system (Yamamoto et al. 1974; Culebras et al. 1977; Narita et al. 1977; Henriksen et al. 1978; Barreca et al. 1980; Mahler and Parizel 1982) . However, the exact sites of lesion in hypothalamus or pituitary gland are not clarified well. Takase (1983) have reported that MyD patients showed more blunted GH responses to L-dopa compared with those to insulin induced hypog lycemia. To clarify this, we examined plasma GH and prolactin (PRL) responses to L-dopa, bromocriptine (dopamine agonist), and sulpiride (dopamine antagonist) in MyD patients who had normal GH responses to insulin and arginine.
SUBJECTS and METHODS
Fifteen patients with MyD (12 males and 3 females), aged 16-49 years (mean 30.9) were examined.
Each All patients and 14 controls were injected with sulpiride (100 mg) intramuscularily. Blood samples were taken before and 30, 60, 90, 120 and 150 min after the injection for the measurement of PRL.
The level of plasma GH and PRL was determined by radioimmunoasssay using commer cially available kits (GH, Dainabot, Tokyo ; PRL, Daiichi RI, Tokyo) and given in terms of mean+s.E. Student's t-test was employed for statistical analysis. 
RESULTS

Growth hormone (GH)
There were no differences in basal levels of plasma GH between MyD patients and controls (Figs. 1 and 2). MyD patients showed a slight increase in plasma GH levels after the administration of L-dopa. Compared with controls, plasma GH response to L-dopa in MyD patients were significantly low at 60, 90 and 150 min (p<0.01, p<0.01 and p<0.05, respectively, Fig. 1 H. Sakcuma et al, of bromocriptine, MyD patients showed a slight increase in plasma GH. However, the response was significantly lower than that of normal controls at 120 min (p <0.01, Fig. 2 ).
Prolactin (PRL)
Although basal levels of plasma PRL in all MyD patients were normal (male, 3.7-18.4 ng/ml ; female, 5.2-23.8 ng/ml), they were slightly lower compared with Fig. 4 controls. Especially in male MyD patients, their basal levels of plasma PRL were significantly lower than those of controls (Fig. 3) . The administration of sulpir ide was followed by sharp increases in plasma PRL levels in both male and female MyD patients, and like in normal subjects, the PRL response to this drug was slightly greater in female patients than in male patients (Figs. 3 and 4) . Compared with controls, however, both male and female MyD patients showed significantly lower responses (Figs. 3 and 4) . After the administration of L-dopa, MyD patients showed a clear decrease of plasma PRL levels. However, the response was significantly lower than controls at 120 min (p <0.05, Fig. 5 ). Bromocriptine also caused a clear decrease in plasma PRL levels in MyD patients. The PRL response in MyD patients was significantly blunted compared with controls at 120, 180 and 240 min (p <0.01, on each occasion, Fig. 6 ). 
DISCUSSION
In this study, we obtained the following findings : 1) basal levels of plasma GH and PRL were within normal ranges, although the PRL levels were slightly lower than controls, 2) both GH and PRL responses to L-dopa and bromocriptine were significantly impaired compared with controls, 3) PRL response to sulpiride was also significantly blunted compared with controls. In our results, plasma PRL response to sulpiride was significantly lower than normal controls. This result might be due to the possibil ity that pituitary PRL reserve is decreased, whereas the possible defect of DA neuron mentioned above may give us the other clue, that is, as the magnitude of PRL response to sulpiride is proportionate to the degree of hypothalamic DA tone exerting to pituitary gland (Hanew et al. 1983), it seems likely that dopaminergic inhibition on the lactotrophs is decreasing. Despite the possible defect of DA neuron and DA receptors mentioned above, the basal PRL levels in MyD patients were rather decreased. Furthermore it differed from previous reports (Henriksen et al. 1978; Mahler and Parizel 1982) . The reason for decreased PRL secretion from lactotrophs is not clear. However, following two explanations might be offered, 1) there exist some defects of the DA receptors in the lactotrophs, 2) the lactotroph cells in MyD patients possess some abnormalities.
The impaired PRL responses to L-dopa and bromocriptine might support these explanations. After L-dopa converts into DA peripherally, DA inhibits the pituitary PRL release directly (Yoshinaga and Sato 1978 
